1. Report Introduction 2. Metastatic Uveal Melanoma (MUM) Market Overview at a Glance 2.1. Market Share Distribution of Metastatic Uveal Melanoma (MUM) in 2017 2.2. Market Share Distribution of Metastatic Uveal Melanoma (MUM) in 2028 3. Disease Background and Overview: Metastatic Uveal Melanoma (MUM) 3.1. Introduction 3.2. Symptoms 3.3. Etiology 3.4. Risk Factors 3.5. Pathophysiology 3.6. Diagnosis 3.7. Treatment 4. Epidemiology and Patient Population 4.1. Key Findings 4.2. Total Prevalent/ Incident Patient Population of Metastatic Uveal Melanoma (MUM) in 7MM 4.3. Total Prevalent Patient Population of Metastatic Uveal Melanoma (MUM) in 7MM – By Countries 5. Epidemiology of Metastatic Uveal Melanoma (MUM) by Countries 5.1. United States 5.1.1. Assumptions and Rationale 5.1.2. Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM) 5.1.3. Sub-Type Specific cases of the Metastatic Uveal Melanoma (MUM) *Indication Specific 5.1.4. Sex- Specific Cases of the Metastatic Uveal Melanoma (MUM) *Indication Specific 5.1.5. Diagnosed Cases of the Metastatic Uveal Melanoma (MUM) 5.1.6. Treatable Cases of the Metastatic Uveal Melanoma (MUM) 5.2. EU5 5.3. Assumptions and Rationale 5.4. Germany 5.4.1. Assumptions and Rationale 5.4.2. Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM) 5.4.3. Sub-Type Specific cases of the Metastatic Uveal Melanoma (MUM) * 5.4.4. Sex- Specific Cases of the Metastatic Uveal Melanoma (MUM) * 5.4.5. Diagnosed Cases of the Metastatic Uveal Melanoma (MUM) 5.4.6. Treatable Cases of the Metastatic Uveal Melanoma (MUM) 5.5. France 5.5.1. Assumptions and Rationale 5.5.2. Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM) 5.5.3. Sub-Type Specific cases of the Metastatic Uveal Melanoma (MUM) * 5.5.4. Sex- Specific Cases of the Metastatic Uveal Melanoma (MUM) * 5.5.5. Diagnosed Cases of the Metastatic Uveal Melanoma (MUM) 5.5.6. Treatable Cases of the Metastatic Uveal Melanoma (MUM) 5.6. Italy 5.6.1. Assumptions and Rationale 5.6.2. Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM) 5.6.3. Sub-Type Specific cases of the Metastatic Uveal Melanoma (MUM) * 5.6.4. Sex- Specific Cases of the Metastatic Uveal Melanoma (MUM) * 5.6.5. Diagnosed Cases of the Metastatic Uveal Melanoma (MUM) 5.6.6. Treatable Cases of the Metastatic Uveal Melanoma (MUM) 5.7. Spain 5.7.1. Assumptions and Rationale 5.7.2. Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM) 5.7.3. Sub-Type Specific cases of the Metastatic Uveal Melanoma (MUM) * 5.7.4. Sex- Specific Cases of the Metastatic Uveal Melanoma (MUM) * 5.7.5. Diagnosed Cases of the Metastatic Uveal Melanoma (MUM) 5.7.6. Treatable Cases of the Metastatic Uveal Melanoma (MUM) 5.8. United Kingdom 5.8.1. Assumptions and Rationale 5.8.2. Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM) 5.8.3. Sub-Type Specific cases of the Metastatic Uveal Melanoma (MUM) * 5.8.4. Sex- Specific Cases of the Metastatic Uveal Melanoma (MUM) * 5.8.5. Diagnosed Cases of the Metastatic Uveal Melanoma (MUM) 5.8.6. Treatable Cases of the Metastatic Uveal Melanoma (MUM) 5.9. Japan 5.9.1. Assumptions and Rationale 5.9.2. Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM) 5.9.3. Sub-Type Specific cases of the Metastatic Uveal Melanoma (MUM) * 5.9.4. Sex- Specific Cases of the Metastatic Uveal Melanoma (MUM) * 5.9.5. Diagnosed Cases of the Metastatic Uveal Melanoma (MUM) 5.9.6. Treatable Cases of the Metastatic Uveal Melanoma (MUM) 6. Current Treatment & Medical practices 6.1. Treatment Algorithm 6.2. Treatment Guidelines 7. Unmet Needs of the Metastatic Uveal Melanoma (MUM) 8. Marketed Therapies 8.1. Drug A: Company 1 8.1.1. Drug Description 8.1.2. Mechanism of Action 8.1.3. Regulatory Milestones 8.1.4. Advantages & Disadvantages 8.1.5. Product Profile 8.2. Drug B: Company 2 8.2.1. Drug Description 8.2.2. Mechanism of Action 8.2.3. Regulatory Milestones 8.2.4. Advantages & Disadvantages 8.2.5. Product Profile 9. Pipeline Therapies – At a glance 10. Key Cross Competition 11. Emerging Therapies for Metastatic Uveal Melanoma (MUM) 11.1. Drug C: Company 3 11.1.1. Drug Description 11.1.2. Clinical Trials Details 11.1.3. Safety and Efficacy Profile 11.1.4. Advantages & Disadvantages 11.1.5. Pipeline Development Activities 11.1.6. Product Profile 11.2. Drug D: Company 4 11.2.1. Drug Description 11.2.2. Clinical Trials Details 11.2.3. Safety and Efficacy Profile 11.2.4. Advantages & Disadvantages 11.2.5. Pipeline Development Activities 11.2.6. Product Profile 12. Metastatic Uveal Melanoma (MUM) : 7MM Market Analysis 12.1. 7MM Market Size of Metastatic Uveal Melanoma (MUM) 12.2. 7MM Percentage Share of drugs marketed for Metastatic Uveal Melanoma (MUM) 12.3. 7MM Market Sales of Metastatic Uveal Melanoma (MUM) by Products 13. Metastatic Uveal Melanoma (MUM) : Country-Wise Market Analysis 13.1. United States 13.1.1. Market Size of Metastatic Uveal Melanoma (MUM) in United States 13.1.2. Percentage Share of drugs marketed for Metastatic Uveal Melanoma (MUM) in United States 13.1.3. Market Sales of Metastatic Uveal Melanoma (MUM) by Products in United States 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2. EU-5 13.2.1. Germany 13.2.1.1. Market Size of Metastatic Uveal Melanoma (MUM) in Germany 13.2.1.2. Percentage Share of drugs marketed for Metastatic Uveal Melanoma (MUM) in Germany 13.2.1.3. Market Sales of Metastatic Uveal Melanoma (MUM) by Products in Germany 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.2. France 13.2.2.1. Market Size of Metastatic Uveal Melanoma (MUM) in France 13.2.2.2. Percentage Share of drugs marketed for Metastatic Uveal Melanoma (MUM) in France 13.2.2.3. Market Sales of Metastatic Uveal Melanoma (MUM) by Products in France 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.3. Italy 13.2.3.1. Market Size of Metastatic Uveal Melanoma (MUM) in Italy 13.2.3.2. Percentage Share of drugs marketed for Metastatic Uveal Melanoma (MUM) in Italy 13.2.3.3. Market Sales of Metastatic Uveal Melanoma (MUM) by Products in Italy 13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.4. Spain 13.2.4.1. Market Size of Metastatic Uveal Melanoma (MUM) in Spain 13.2.4.2. Percentage Share of drugs marketed for Metastatic Uveal Melanoma (MUM) in Spain 13.2.4.3. Market Sales of Metastatic Uveal Melanoma (MUM) by Products in Spain 13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.5. United Kingdom 13.2.5.1. Market Size of Metastatic Uveal Melanoma (MUM) in United Kingdom 13.2.5.2. Percentage Share of drugs marketed for Metastatic Uveal Melanoma (MUM) in United Kingdom 13.2.5.3. Market Sales of Metastatic Uveal Melanoma (MUM) by Products in United Kingdom 13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market 13.3. Japan 13.3.1. Market Size of Metastatic Uveal Melanoma (MUM) in Japan 13.3.2. Percentage Share of drugs marketed for Metastatic Uveal Melanoma (MUM) in Japan 13.3.3. Market Sales of Metastatic Uveal Melanoma (MUM) by Products in Japan 13.3.4. Analysis of Upcoming Therapies and their Impact on the Market 14. Market Drivers 15. Market Barriers 16. Appendix 17. Report Methodology 17.1. Sources 18. DelveInsight Capabilities 19. Disclaimer 20. About DelveInsight

Table 1: Total Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM) in 7MM Table 2: Total Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM) in 7MM by Countries Table 3: Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM) in United States (2017-2028) Table 4: Sub-Type Specific cases of the Metastatic Uveal Melanoma (MUM) in United States (2017-2028) Table 5: Sex- Specific Cases of the Metastatic Uveal Melanoma (MUM) in United States (2017-2028) Table 6: Diagnosed Cases of the Metastatic Uveal Melanoma (MUM) in United States (2017-2028) Table 7: Treatable Cases of the Metastatic Uveal Melanoma (MUM) in United States (2017-2028) Table 8: Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM) in Germany (2017-2028) Table 9: Sub-Type Specific cases of the Metastatic Uveal Melanoma (MUM) in Germany (2017-2028) Table 10: Sex- Specific Cases of the Metastatic Uveal Melanoma (MUM) in Germany (2017-2028) Table 11: Diagnosed Cases of the Metastatic Uveal Melanoma (MUM) in Germany (2017-2028) Table 12: Treatable Cases of the Metastatic Uveal Melanoma (MUM) in Germany (2017-2028) Table 13: Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM) in France (2017-2028) Table 14: Sub-Type Specific cases of the Metastatic Uveal Melanoma (MUM) in France (2017-2028) Table 15: Sex- Specific Cases of the Metastatic Uveal Melanoma (MUM) in France (2017-2028) Table 16: Diagnosed Cases of the Metastatic Uveal Melanoma (MUM) in France (2017-2028) Table 17: Treatable Cases of the Metastatic Uveal Melanoma (MUM) in France (2017-2028) Table 18: Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM) in Italy (2017-2028) Table 19: Sub-Type Specific cases of the Metastatic Uveal Melanoma (MUM) in Italy (2017-2028) Table 20: Sex- Specific Cases of the Metastatic Uveal Melanoma (MUM) in Italy (2017-2028) Table 21: Diagnosed Cases of the Metastatic Uveal Melanoma (MUM) in Italy (2017-2028) Table 22: Treatable Cases of the Metastatic Uveal Melanoma (MUM) in Italy (2017-2028) Table 23: Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM) in Spain (2017-2028) Table 24: Sub-Type Specific cases of the Metastatic Uveal Melanoma (MUM) in Spain (2017-2028) Table 25: Sex- Specific Cases of the Metastatic Uveal Melanoma (MUM) in Spain (2017-2028) Table 26: Diagnosed Cases of the Metastatic Uveal Melanoma (MUM) in Spain (2017-2028) Table 27: Treatable Cases of the Metastatic Uveal Melanoma (MUM) in Spain (2017-2028) Table 28: Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM) in UK (2017-2028) Table 29: Sub-Type Specific cases of the Metastatic Uveal Melanoma (MUM) in UK (2017-2028) Table 30: Sex- Specific Cases of the Metastatic Uveal Melanoma (MUM) in UK (2017-2028) Table 31: Diagnosed Cases of the Metastatic Uveal Melanoma (MUM) in UK (2017-2028) Table 32: Treatable Cases of the Metastatic Uveal Melanoma (MUM) in UK (2017-2028) Table 33: Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM) in Japan (2017-2028) Table 34: Sub-Type Specific cases of the Metastatic Uveal Melanoma (MUM) in Japan (2017-2028) Table 35: Sex- Specific Cases of the Metastatic Uveal Melanoma (MUM) in Japan (2017-2028) Table 36: Diagnosed Cases of the Metastatic Uveal Melanoma (MUM) in Japan (2017-2028) Table 37: Treatable Cases of the Metastatic Uveal Melanoma (MUM) in Japan (2017-2028) Table 38: Marketed Therapies Table 39: Emerging Therapies Table 40: Key Cross Competition Table 41:7MM- Market Size of Metastatic Uveal Melanoma (MUM) in USD MM (2017-2028) Table 42:7MM- Market Share Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028) Table 43:7MM- Market Sales of Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028) Table 44: United States-Market Size of Metastatic Uveal Melanoma (MUM) in USD MM (2017-2028) Table 45: United States-Market Share Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028) Table 46: United States-Market Sales of Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028) Table 47: Germany-Market Size of Metastatic Uveal Melanoma (MUM) in USD MM (2017-2028) Table 48: Germany-Market Share Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028) Table 49: Germany-Market Sales of Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028) Table 50: France-Market Size of Metastatic Uveal Melanoma (MUM) in USD MM (2017-2028) Table 51: France-Market Share Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028) Table 52: France-Market Sales of Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028) Table 53: Italy-Market Size of Metastatic Uveal Melanoma (MUM) in USD MM (2017-2028) Table 54: Italy-Market Share Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028) Table 55: Italy-Market Sales of Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028) Table 56: Spain-Market Size of Metastatic Uveal Melanoma (MUM) in USD MM (2017-2028) Table 57: Spain-Market Share Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028) Table 58: Spain-Market Sales of Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028) Table 59:UK-Market Size of Metastatic Uveal Melanoma (MUM) in USD MM (2017-2028) Table 60:UK-Market Share Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028) Table 61:UK-Market Sales of Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028) Table 62: Japan-Market Size of Metastatic Uveal Melanoma (MUM) in USD MM (2017-2028) Table 63: Japan-Market Share Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028) Table 64: Japan-Market Sales of Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028) Figure 1: Total Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM) in 7MM Figure 2: Total Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM) in 7MM by Countries Figure 3: Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM) in United States (2017-2028) Figure 4: Sub-Type Specific cases of the Metastatic Uveal Melanoma (MUM) in United States (2017-2028) Figure 5: Sex- Specific Cases of the Metastatic Uveal Melanoma (MUM) in United States (2017-2028) Figure 6: Diagnosed Cases of the Metastatic Uveal Melanoma (MUM) in United States (2017-2028) Figure 7: Treatable Cases of the Metastatic Uveal Melanoma (MUM) in United States (2017-2028) Figure 8: Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM) in Germany (2017-2028) Figure 9: Sub-Type Specific cases of the Metastatic Uveal Melanoma (MUM) in Germany (2017-2028) Figure 10: Sex- Specific Cases of the Metastatic Uveal Melanoma (MUM) in Germany (2017-2028) Figure 11: Diagnosed Cases of the Metastatic Uveal Melanoma (MUM) in Germany (2017-2028) Figure 12: Treatable Cases of the Metastatic Uveal Melanoma (MUM) in Germany (2017-2028) Figure 13: Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM) in France (2017-2028) Figure 14: Sub-Type Specific cases of the Metastatic Uveal Melanoma (MUM) in France (2017-2028) Figure 15: Sex- Specific Cases of the Metastatic Uveal Melanoma (MUM) in France (2017-2028) Figure 16: Diagnosed Cases of the Metastatic Uveal Melanoma (MUM) in France (2017-2028) Figure 17: Treatable Cases of the Metastatic Uveal Melanoma (MUM) in France (2017-2028) Figure 18: Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM) in Italy (2017-2028) Figure 19: Sub-Type Specific cases of the Metastatic Uveal Melanoma (MUM) in Italy (2017-2028) Figure 20: Sex- Specific Cases of the Metastatic Uveal Melanoma (MUM) in Italy (2017-2028) Figure 21: Diagnosed Cases of the Metastatic Uveal Melanoma (MUM) in Italy (2017-2028) Figure 22: Treatable Cases of the Metastatic Uveal Melanoma (MUM) in Italy (2017-2028) Figure 23: Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM) in Spain (2017-2028) Figure 24: Sub-Type Specific cases of the Metastatic Uveal Melanoma (MUM) in Spain (2017-2028) Figure 25: Sex- Specific Cases of the Metastatic Uveal Melanoma (MUM) in Spain (2017-2028) Figure 26: Diagnosed Cases of the Metastatic Uveal Melanoma (MUM) in Spain (2017-2028) Figure 27: Treatable Cases of the Metastatic Uveal Melanoma (MUM) in Spain (2017-2028) Figure 28: Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM) in UK (2017-2028) Figure 29: Sub-Type Specific cases of the Metastatic Uveal Melanoma (MUM) in UK (2017-2028) Figure 30: Sex- Specific Cases of the Metastatic Uveal Melanoma (MUM) in UK (2017-2028) Figure 31: Diagnosed Cases of the Metastatic Uveal Melanoma (MUM) in UK (2017-2028) Figure 32: Treatable Cases of the Metastatic Uveal Melanoma (MUM) in UK (2017-2028) Figure 33: Prevalent/Incident Cases of the Metastatic Uveal Melanoma (MUM) in Japan (2017-2028) Figure 34: Sub-Type Specific cases of the Metastatic Uveal Melanoma (MUM) in Japan (2017-2028) Figure 35: Sex- Specific Cases of the Metastatic Uveal Melanoma (MUM) in Japan (2017-2028) Figure 36: Diagnosed Cases of the Metastatic Uveal Melanoma (MUM) in Japan (2017-2028) Figure 37: Treatable Cases of the Metastatic Uveal Melanoma (MUM) in Japan (2017-2028) Figure 38: Marketed Therapies Figure 39: Emerging Therapies Figure 40: Key Cross Competition Figure 41:7MM- Market Size of Metastatic Uveal Melanoma (MUM) in USD MM (2017-2028) Figure 42:7MM- Market Share Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028) Figure 43:7MM- Market Sales of Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028) Figure 44: United States-Market Size of Metastatic Uveal Melanoma (MUM) in USD MM (2017-2028) Figure 45: United States-Market Share Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028) Figure 46: United States-Market Sales of Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028) Figure 47: Germany-Market Size of Metastatic Uveal Melanoma (MUM) in USD MM (2017-2028) Figure 48: Germany-Market Share Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028) Figure 49: Germany-Market Sales of Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028) Figure 50: France-Market Size of Metastatic Uveal Melanoma (MUM) in USD MM (2017-2028) Figure 51: France-Market Share Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028) Figure 52: France-Market Sales of Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028) Figure 53: Italy-Market Size of Metastatic Uveal Melanoma (MUM) in USD MM (2017-2028) Figure 54: Italy-Market Share Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028) Figure 55: Italy-Market Sales of Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028) Figure 56: Spain-Market Size of Metastatic Uveal Melanoma (MUM) in USD MM (2017-2028) Figure 57: Spain-Market Share Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028) Figure 58: Spain-Market Sales of Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028) Figure 59:UK-Market Size of Metastatic Uveal Melanoma (MUM) in USD MM (2017-2028) Figure 60:UK-Market Share Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028) Figure 61:UK-Market Sales of Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028) Figure 62: Japan-Market Size of Metastatic Uveal Melanoma (MUM) in USD MM (2017-2028) Figure 63: Japan-Market Share Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028) Figure 64: Japan-Market Sales of Metastatic Uveal Melanoma (MUM) by Therapies in USD MM (2017-2028)